Sugi Predict

Sugi Predict / Compounds / SCHEMBL1114093

SCHEMBL1114093

SCHEMBL1114093

CC(C)(C)OC(=O)N1CCC(CBr)C1

nearest known ligand 0.51

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ NR1H2 P55055 1/20 0.49
▸ HPGD P15428 1/20 0.48
▸ KDM4E B2RXH2 1/20 0.47
▸ PKM P14618 1/20 0.47
▸ MEN1 O00255 1/20 0.47
▸ ALDH1A1 P00352 1/20 0.47
▸ MAPT P10636 1/20 0.47
▸ KMT2A Q03164 1/20 0.47
▸ IDO1 P14902 1/20 0.46
▸ TDO2 P48775 1/20 0.46
▸ RECQL P46063 1/20 0.46
▸ EPHX1 P07099 1/20 0.46
▸ GLS O94925 2/20 0.44
▸ USP2 O75604 1/20 0.44
▸ SMN1; SMN2 Q16637 1/20 0.44
▸ GPR119 Q8TDV5 3/20 0.43
▸ FAAH O00519 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13604586 1.00 NR1H2 (0.49) NR1H2HPGDKDM4EPKMMEN1
SCHEMBL14920966 1.00 NR1H2 (0.49) NR1H2HPGDKDM4EPKMMEN1
SCHEMBL30294023 1.00 NR1H2 (0.49) NR1H2HPGDKDM4EPKMMEN1
SCHEMBL1978233 0.91 MEN1 (0.54) NR1H2HPGDMEN1ALDH1A1MAPT
SCHEMBL1974493 0.91 MEN1 (0.54) NR1H2HPGDMEN1ALDH1A1MAPT
SCHEMBL376819 0.91 MEN1 (0.54) NR1H2HPGDMEN1ALDH1A1MAPT
SCHEMBL8206 0.90 HPGD (0.54) NR1H2HPGDKDM4EPKMMAPT
SCHEMBL25625800 0.90 NR1H2 (0.51) NR1H2HPGDKDM4EPKMMEN1
SCHEMBL3247525 0.88 NR1H2 (0.47) NR1H2HPGDKDM4EPKMMEN1
SCHEMBL14921079 0.88 NR1H2 (0.47) NR1H2HPGDKDM4EPKMMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 206 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260055099-A1 PROTACS FOR TARGETED DEGRADATION OF KAT2A AND KAT2B FOR THE TREATMENT OF CANCER UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) 2026-02-26 — — US disclosed
US-12544448-B2 C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors Revolution Medicines, Inc. (US) 2026-02-10 — — US disclosed
US-12503473-B2 Triazolopyrimidine compounds and their use in treating cancer DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) 2025-12-23 — — US disclosed
EP-4658640-A1 PYRIDIN-2(1H)-ONES AND PYRIMIDIN-4(3H)-ONES AS NLRP3 INHIBITORS Janssen Pharmaceutica NV (BE) 2025-12-10 — — EP disclosed
WO-2025108255-A1 POLYCYCLIC DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF 上海齐鲁制药研究中心有限公司 2025-05-30 — — WO disclosed
EP-4551571-A1 OXAZOLE TRPML1 AGONISTS AND USES THEREOF Libra Therapeutics, Inc. (US) 2025-05-14 — — EP disclosed
EP-4543879-A1 PROTACS FOR TARGETED DEGRADATION OF KAT2A AND KAT2B FOR THE TREATMENT OF CANCER University College Cardiff Consultants Limited (GB) 2025-04-30 — — EP disclosed
US-20250108117-A1 C40-, C28-, and C-32-Linked Rapamycin Analogs as mTOR Inhibitors WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT 2025-04-03 — — US disclosed
US-12187746-B2 C26-linked rapamycin analogs as mTOR inhibitors Revolution Medicines, Inc. (US) 2025-01-07 — — US disclosed
CN-118955490-A O-glycoprotein-2-acetamido-2-deoxy-3-D-pyranoside enzyme inhibitors 渤健马萨诸塞州股份有限公司 2024-11-15 — — CN disclosed
US-20090275585-A1 Novel Compounds and Therapeutic Use Thereof for Protein Kinase Inhibition WU ZHANGGUI 2009-11-05 — — US disclosed
US-20090275585-A1 Novel Compounds and Therapeutic Use Thereof for Protein Kinase Inhibition WU ZHANGGUI 2009-11-05 — — US disclosed
US-20090118324-A1 MAPK/ERK KINASE INHIBITORS TAKEDA SAN DIEGO, INC. 2009-05-07 — — US disclosed
WO-2008121685-A1 METHODS OF USE FOR INHIBITORS OF AKT ACTIVITY SMITHKLINE BEECHAM CORPORATION (US) 2008-10-09 — — WO disclosed
EP-1948188-A2 INHIBITORS OF AKT ACTIVITY SmithKline Beecham Corporation (US) 2008-07-30 — — EP disclosed
US-20080076763-A1 Inhibitors of Akt activity GLAXOSMITHKLINE LLC 2008-03-27 — — US disclosed
WO-2007058850-A2 INHIBITORS OF AKT ACTIVITY SMITHKLINE BEECHAM CORPORATION (US) 2007-05-24 — — WO disclosed
US-7071175-B1 Pyridine mercapto carboxylic acids as carboxypeptidase U inhibitors ASTRAZENECA AB (SE) 2006-07-04 — — US disclosed
EP-1180098-A1 NEW COMPOUNDS AstraZeneca AB (SE) 2002-02-20 — — EP disclosed
WO-2000066557-A1 NEW COMPOUNDS ASTRAZENECA AB (SE) 2000-11-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12503473-B2 Triazolopyrimidine compounds and their use in treating cancer ABCC4, ABCB1, SLC16A3 NR1H2 2807/4885HPGD 1445/4885KDM4E 1071/4885
US-20250108117-A1 C40-, C28-, and C-32-Linked Rapamycin Analogs as mTOR Inhibitors MTOR, RICTOR, RPTOR NR1H2 3048/4885HPGD 4292/4885KDM4E 1313/4885
US-12187746-B2 C26-linked rapamycin analogs as mTOR inhibitors MTOR, RICTOR, RPTOR NR1H2 3013/4885HPGD 3675/4885KDM4E 1155/4885
US-20080076763-A1 Inhibitors of Akt activity PI4KB, PIK3CA, AKT2 NR1H2 4137/4885HPGD 3723/4885KDM4E 2078/4885
US-20090118324-A1 MAPK/ERK KINASE INHIBITORS MAPK1, MAP3K1, MAP3K7 NR1H2 2015/4885HPGD 644/4885KDM4E 2011/4885
US-20260055099-A1 PROTACS FOR TARGETED DEGRADATION OF KAT2A AND KAT2B FOR THE TREATMENT OF CANCER KAT2A, KAT2B, KAT8 NR1H2 87/4885HPGD 4467/4885KDM4E 259/4885
US-20090275585-A1 Novel Compounds and Therapeutic Use Thereof for Protein Kinase Inhibition CHEK2, CHEK1, PLK1 NR1H2 2765/4885HPGD 2757/4885KDM4E 1966/4885
US-12544448-B2 C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors RICTOR, MTOR, MLST8 NR1H2 2545/4885HPGD 4561/4885KDM4E 407/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.